Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409551 | 0.78 | — | — | |
| SCHEMBL19733390 | 0.73 | RET (0.36) | RET | |
| SCHEMBL29321147 | 0.71 | PIK3CD (0.34) | RET | |
| SCHEMBL15101795 | 0.68 | — | — | |
| SCHEMBL19778181 | 0.65 | — | — | |
| SCHEMBL18593488 | 0.65 | MEN1 (0.44) | GSK3B | |
| SCHEMBL10257799 | 0.65 | LMNA (0.41) | — | |
| SCHEMBL10248964 | 0.65 | NOS2 (0.40) | RET | |
| SCHEMBL13968298 | 0.65 | NFATC1 (0.33) | NFATC1GSK3BDYRK1A | |
| SCHEMBL26253554 | 0.65 | PDE4A (0.39) | GSK3BDYRK1ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | NFATC1 127/4885GSK3B 433/4885DYRK1A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.